Literature DB >> 23165887

Medication errors and adverse drug events in kidney transplant recipients: incidence, risk factors, and clinical outcomes.

David J Taber1, Nicole A Pilch, Charles F Bratton, John W McGillicuddy, Kenneth D Chavin, Prabhakar K Baliga.   

Abstract

STUDY
OBJECTIVE: To determine the incidence, risk factors, and clinical outcomes associated with clinically significant medication errors or adverse drug events in kidney transplant recipients.
DESIGN: Retrospective observational study.
SETTING: Transplant center at an academic medical center. PATIENTS: A total of 476 adults who received kidney transplants between June 2006 and July 2009.
MEASUREMENTS AND MAIN RESULTS: Severe or significant medication errors and adverse drug events (medication-related problems [MRPs]) were identified by medical record review. Only patient-induced medication errors (e.g., took wrong dose or frequency of drug, took drug not prescribed) were captured. Clinical outcomes included patient and graft survival, infections (including cytomegalovirus), readmissions, and acute rejection episodes. Thirty-seven (8%) of the 476 patients developed a clinically significant MRP. Univariate and confirmatory multivariate analyses revealed that female sex, African-American race, pretransplantation diabetes mellitus, delayed graft function, and retransplant recipients were independent risk factors for developing an MRP. Patients with MRPs had significantly higher rates of acute rejection (11% vs 30%, p=0.004), cytomegalovirus infection (15% vs 30%, p=0.033), and 30-day readmissions (5% vs 16%, p=0.018). Graft survival was also significantly lower in patients who had MRPs (p<0.001).
CONCLUSION: Patient-induced medication errors and associated adverse drug events were common in kidney transplant recipients. General and transplant-specific risk factors were associated with the development of these MRPs, and MRPs were associated with increased risk of rejection and graft loss.
© 2012 Pharmacotherapy Publications, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23165887     DOI: 10.1002/phar.1145

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  14 in total

1.  Value of solid organ transplant-trained pharmacists in transplant infectious diseases.

Authors:  Jennifer Trofe-Clark; Tiffany Kaiser; Nicole Pilch; David Taber
Journal:  Curr Infect Dis Rep       Date:  2015-04       Impact factor: 3.725

2.  Clinical and economic outcomes associated with medication errors in kidney transplantation.

Authors:  David J Taber; Justin R Spivey; Victoria M Tsurutis; Nicole A Pilch; Holly B Meadows; James N Fleming; John W McGillicuddy; Charles F Bratton; Frank A Treiber; Prabhakar K Baliga; Kenneth D Chavin
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

3.  Quantifying the Race Stratified Impact of Socioeconomics on Graft Outcomes in Kidney Transplant Recipients.

Authors:  David J Taber; Mahsa Hamedi; James R Rodrigue; Mulugeta G Gebregziabher; Titte R Srinivas; Prabhakar K Baliga; Leonard E Egede
Journal:  Transplantation       Date:  2016-07       Impact factor: 4.939

Review 4.  Racial and Ethnic Disparities in Adverse Drug Events: A Systematic Review of the Literature.

Authors:  Avi Baehr; Juliet C Peña; Dale J Hu
Journal:  J Racial Ethn Health Disparities       Date:  2015-03-24

5.  Pharmacist-Led, Technology-Assisted Study to Improve Medication Safety, Cardiovascular Risk Factor Control, and Racial Disparities in Kidney Transplant Recipients.

Authors:  David J Taber; Mulugeta Gebregziabher; Aurora Posadas; Caitlin Schaffner; Leonard E Egede; Prabhakar K Baliga
Journal:  J Am Coll Clin Pharm       Date:  2018-06-21

6.  Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety: A Randomized Controlled Clinical Trial.

Authors:  Haley M Gonzales; James N Fleming; Mulugeta Gebregziabher; Maria Aurora Posadas-Salas; Zemin Su; John W McGillicuddy; David J Taber
Journal:  Clin J Am Soc Nephrol       Date:  2021-04-30       Impact factor: 8.237

7.  Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol.

Authors:  James N Fleming; Frank Treiber; John McGillicuddy; Mulugeta Gebregziabher; David J Taber
Journal:  JMIR Res Protoc       Date:  2018-03-02

8.  Development and validation of PART (Pharmacotherapy Assessment in Renal Transplant Patients) criteria to assess drug-related problems in an outpatient renal transplant population: A cross-sectional study.

Authors:  Layal El Raichani; Qian Du; Alexandre Mathieu; Sabrina Almassy; Lyne Lalonde; Djamal Berbiche; Elisabeth Gélinas-Lemay; Nathalie Boudreau; Héloïse Cardinal
Journal:  Pharmacol Res Perspect       Date:  2019-01-15

9.  Improving Transplant Medication Safety Through a Technology and Pharmacist Intervention (ISTEP): Protocol for a Cluster Randomized Controlled Trial.

Authors:  Casey L Hall; Cory E Fominaya; Mulugeta Gebregziabher; Sherry K Milfred-LaForest; Kelsey M Rife; David J Taber
Journal:  JMIR Res Protoc       Date:  2019-10-01

Review 10.  Follow-up of liver transplant recipients.

Authors:  James Neuberger
Journal:  Best Pract Res Clin Gastroenterol       Date:  2020-09-11       Impact factor: 3.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.